Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2010 Apr;138(4):1240-3.
doi: 10.1053/j.gastro.2010.02.033. Epub 2010 Feb 23.

Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle

Chloe L Thio, David L Thomas
Editorial

Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle

Chloe L Thio et al. Gastroenterology. 2010 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

The authors declare no conflicts.

Figures

Figure 1
Figure 1
HCV RNA triggers production of type 1 interferons (such as interferon β and interferon α) and probably lambda interferons by hepatocytes, and these molecules (and probably the virus itself) stimulate transcription of interferon stimulated genes (ISGs) in antigen presenting cells such as dendritic cells as well as in hepatocytes. Exogenous (therapeutic) interferon α and lambda interferon signal similarly, but in a “steady-state” environment in which HCV replication has been sustained despite ongoing expression of ISGs. Polymorphisms just upstream of the gene for IL-28b (interferon lambda 3) are strongly associated with spontaneous and treatment-associated resolution of HCV infection, but the mechanism is unknown.
See this image and copyright information in PMC

Comment on

  • Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.
    Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY; Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Rauch A, et al. Gastroenterology. 2010 Apr;138(4):1338-45, 1345.e1-7. doi: 10.1053/j.gastro.2009.12.056. Epub 2010 Jan 11. Gastroenterology. 2010. PMID: 20060832

References

    1. Jessner W, Gschwantler M, Steindl-Munda P, et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet. 2001;358:1241–1242. - PubMed
    1. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677–684. - PubMed
    1. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450–456. - PubMed
    1. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340:1228–1233. - PubMed
    1. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med. 2009;360:257–267. - PubMed